MedWatch

Biogen's Aduhelm rejected by EMA committee

As expected, the European Medicines Agency's (EMA) special committee, the CHMP, has given a negative opinion on Alzheimer's treatment, Aduhelm, as Biogen proved unable to convince the authority to approve the drug as managed to do in the US.

Photo: POOL New/VIA REUTERS / X80003

On Friday, Alzheimer's drug Aduhelm, which pharmaceutical firm Biogen is behind, has been rejected by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs